Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial